AUTHOREA
Log in
Sign Up
Browse Preprints
LOG IN
SIGN UP
Please note
: Importing new articles from Word documents is currently unavailable. We are working on fixing this issue soon and apologize for any inconvenience.
Colleen Sakon
Public Documents
1
A survey assesing the impact of COVID-19 and elexacaftor/tezacaftor/ifavacaftor on bo...
Colleen Sakon
and 3 more
August 22, 2022
While our survey showed that PwCF felt that the COVID-19 pandemic had impacted their mental health more than ETI therapy, around 9% of survey responders felt that ETI did cause an increase in either anxiety or depression. This finding was similar to the numbers Spoletini and colleagues found in their adult clinic. They also found that a dose reduction of ETI improved or resolved mental health adverse events for most patients. [2] A recently published study by Guimbellot and colleagues studied ivacaftor levels in PwCF who were on ivacaftor monotherapy and showed many patients had levels higher than the published minimum effective concentrations.[6] Thus, there may be a correlation between ETI levels and mental health adverse events that should be further explored in a prospective manner.